Global Breast Cancer Screening Test Market Size (2024 - 2029)

Breast Cancer Screening Test Market Analysis

The Global Breast Cancer Screening Test Market size is estimated at USD 2.95 billion in 2024, and is expected to reach USD 4.45 billion by 2029, growing at a CAGR of 8.55% during the forecast period (2024-2029).

The COVID-19 pandemic significantly impacted the breast cancer screening test market due to the halt of breast cancer screening to minimize the spread of infection. For instance, according to the study published in October 2021 by the Journal of Medical Screening, many breast imaging practices purposely stopped mammograms to reduce patient and staff exposure to the virus during the COVID-19 pandemic. This significantly impacted the market growth during the pandemic. However, breast cancer screening remained important during the COVID-19 pandemic, for which various healthcare institutions conducted virtual webinars and telehealth consultations to manage breast cancer during COVID-19. Breast cancer awareness month is celebrated in October every year on a global level to educate women about diagnostic imaging tests and the importance of early screening. The annual international health campaign aims to raise disease awareness and fund research into its cause, prevention, diagnosis, treatment, and cure. Though the COVID-19 pandemic substantially impacted the market in its initial phases, the market recovered in the last two years since the restrictions were lifted and diagnostic centers resumed screening tests leading to a higher demand for screening machines.

Factors responsible for the growth of this market include the increasing awareness about the early detection of breast cancer, the growing incidence of breast cancer, and the increasing government initiatives and support. Early detection of breast cancer can lead to desired outcomes, including increased survival rate, number of treatment options, and improved quality of life. The rising incidence of breast cancer is helping the market to grow in the forecast period. As per Breastcancer.org, updated in July 2022, 287,850 new cases of invasive breast cancer are expected to be diagnosed in the United States, along with 51,400 new cases of non-invasive (in situ) breast cancer cases. Since there is a rising need for breast cancer screening tests across developing and developed nations, the market is expected to grow during the forecast period.

Furthermore, the rising initiative of key players in developing innovative strategies is expected to drive market growth over the forecast period. For instance, in March 2022, LifeCell launched Breast Screen Panel, a comprehensive genetic screening test assessing women's risk of breast cancer. Such initiatives will lead to increased adoption of breast cancer screening, driving the market growth.

However, controversies related to mammography and the high cost of screening tests are expected to hinder the market growth.

Breast Cancer Screening Test Industry Segmentation

As per the scope, breast cancer screening is carried out to detect cancer early and ensure timely treatment for the patients. Different types of breast cancer depend on the type of cancer cell that becomes cancerous. Breast cancer can affect different parts of the breast, such as the ducts and the lobes. The Breast Cancer, Screening Test Market, is Segmented by Test (Genomic Tests and Imaging Tests) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.